The validated IGA for atopic dermatitis tool proved to be a reliable and accurate means to assess disease severity and quality of life among adults, adolescents and pediatric patients, according to a study.
The validated IGA for atopic dermatitis (vIGA-AD) was first published in 2020 in order to create a standardized, global way to measure AD severity. It has since been revalidated through baricitinib and upadacitinib clinical studies, in addition to being used in other phase 3 studies.
A study was recently published in the Journal of Drugs in Dermatology to assess the relationship between